Skip to content
OpenCapital
Get started

Denali Therapeutics Inc. DNLI Cash ratio

Cash ratio at other companies

Eli Lilly logo
Eli LillyLLY
0.1×0.0×
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
0.6×-0.3×
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
0.5×+0.1×
Viking Therapeutics logo
Viking TherapeuticsVKTX
1.1×-0.8×
uniQure logo
uniQureQURE
2.4×-3.6×
Biogen logo
BiogenBIIB
1.1×+0.6×

Other financials

Income statement

See full
Revenue-—
Operating income-$137.4M+5.6%
Net income-$128.4M+3.4%
EPS (diluted)-$0.69+11.5%

Balance sheet

See full
Cash & equivalents$390.7M+551%
Total debt$40.0M-22.3%
Total equity$926.1M-17.5%
Total assets$1.3B-0.4%

Cash flow

See full
Operating cash flow-$131.2M+0.2%
CapEx$2.5M-51.4%
Free cash flow-$133.7M+2.1%

Valuation

See full
Market cap$3.93B+54.2%

Profitability

See full
Operating margin-37,938%-37,986pp
Net margin-33,121.9%-33,159pp
FCF margin-31,736.3%-31,830pp

Returns & leverage

See full
Return on equity-49.6%+34.2pp
Debt / equity0×0.0×
Current ratio9.3×-0.3×

Where this comes from

Calculated from Denali Therapeutics Inc.’s reported figures.

cash and equivalents/total current liabilities=3.5×

Based on the most recent quarter.

The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Denali Therapeutics Inc.'s cash ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Denali Therapeutics Inc.'s cash ratio?
Denali Therapeutics Inc. (DNLI) reported cash ratio of 3.5× in Q1 2026.
How has Denali Therapeutics Inc.'s cash ratio changed year-over-year?
Denali Therapeutics Inc.'s cash ratio increased by 442.7% year-over-year, from 0.7× to 3.5×.
What is the long-term trend for Denali Therapeutics Inc.'s cash ratio?
Over 5 years (2020 to 2025), Denali Therapeutics Inc.'s cash ratio has grown at a -21.5% compound annual growth rate (CAGR), from 7.1× to 2.1×.
What does cash ratio mean?
Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.